Retraction: Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality (New England Journal of Medicine (2018) 378 (1509-1520) DOI: 10.1056/NEJMoa1712231);Relationship between clinic and ambulatory blood-pressure measurements and mortality

New England Journal of Medicine

Volumn 378, Issue 16, 2018, Pages 1509-1520

  Banegas, J R ^a   Ruilope, L M ^a,b,c   De La Sierra, A ^d   Vinyoles, E ^e   Gorostidi, M ^f   De La Cruz, J J ^a   Ruiz Hurtado, G ^b   Segura, J ^b   Rodriguez Artalejo F ^a   Williams, B ^g  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSIDAD EUROPEA DE MADRID   (Spain)

^d HOSPITAL MÚTUA DE TERRASSA   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONFOUNDING VARIABLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEALTH CARE PRACTICE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MASKED HYPERTENSION; MIDDLE AGED; MORTALITY RISK; MOUSE; NONHUMAN; PHENOTYPE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; SPAIN; SUSTAINED HYPERTENSION; SYSTOLIC BLOOD PRESSURE; WHITE COAT HYPERTENSION; BLOOD PRESSURE MEASUREMENT; CAUSE OF DEATH; CLINICAL TRIAL; COMPLICATION; EPIDEMIOLOGY; MALE; MORTALITY; MULTICENTER STUDY; PHYSIOLOGY; PROCEDURES; RISK FACTOR;

AGED; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MASKED HYPERTENSION; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SPAIN; WHITE COAT HYPERTENSION;

EID: 85045836357     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc2001445     Document Type: Erratum

References (40)

1. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006; 354: 2368-74.
2. Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and limits. Circ Res 2015; 116: 1034-45.
3. Staessen JA, Li Y, Hara A, Asayama K, Dolan E, O'Brien E. Blood pressure measurement Anno 2016. Am J Hypertens 2017; 30: 453-63.
4. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111: 1777-83.
5. Kikuya M, Ohkubo T, Asayama K, et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. Hypertension 2005; 45: 240-5.
6. Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 2007; 370: 1219-29.
7. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure and mortality: a population- based study. Hypertension 2005; 45: 499-504.
8. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282: 539-46.
9. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 2407-15.
10. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin Outcome Study. Hypertension 2005; 46: 156-61.
11. Fagard RH, Van Den Broeke C, De Cort P. Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. J Hum Hypertens 2005; 19: 801-7.
12. Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008; 51: 55-61.
13. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension 2011; 57: 3-10.
14. Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol 2005; 46: 508-15.
15. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006; 47: 846-53.
16. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens 2007; 25: 2193-8.
17. Ben-Dov IZ, Kark JD, Mekler J, Shaked E, Bursztyn M. The white coat phenomenon is benign in referred treated patients: a 14-year ambulatory blood pressure mortality study. J Hypertens 2008; 26: 699-705.
18. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens 2011; 24: 52-8.
19. Franklin SS, Thijs L, Hansen TW, et al. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension 2012; 59: 564-71.
20. Franklin SS, Thijs L, Asayama K, et al. The cardiovascular risk of white-coat hypertension. J Am Coll Cardiol 2016; 68: 2033-43.
21. Verdecchia P, Angeli F, Gattobigio R, et al. The clinical significance of whitecoat and masked hypertension. Blood Press Monit 2007; 12: 387-9.
22. Franklin SS, Thijs L, Hansen TW, O'Brien E, Staessen JA. White-coat hypertension: new insights from recent studies. Hypertension 2013; 62: 982-7.
23. Mancia G, Grassi G. The heterogeneous nature of white-coat hypertension. J Am Coll Cardiol 2016; 68: 2044-6.
24. Banegas JR, Ruilope LM, de la Sierra A, et al. High prevalence of masked uncontrolled hypertension in people with treated hypertension. Eur Heart J 2014; 35: 3304-12.
25. Gorostidi M, Banegas JR, de la Sierra A, Vinyoles E, Segura J, Ruilope LM. Ambulatory blood pressure monitoring in daily clinical practice - the Spanish ABPM Registry experience. Eur J Clin Invest 2016; 46: 92-8.
26. O'Brien E, Asmar R, Beilin L, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21: 821-48.
27. O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013; 31: 1731-68.
28. Parati G, Stergiou G, O'Brien E, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014; 32: 1359-66.
29. Instituto Nacional de Estadistica. Estadistica de defunciones segun la causa de muerte. Madrid, Spain: Informes Metodologicos Estandarizados, 2018 (http:// www .ine .es/ dynt3/ metadatos/ es/ Respuesta Print .html?oper=23).
30. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928-35.
31. Brenner H, Gefeller O, Greenland S. Risk and rate advancement periods as measures of exposure impact on the occurrence of chronic diseases. Epidemiology 1993; 4: 229-36.
32. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. Belmont, CA: Lifetime Learning, 1982.
33. Asayama K, Thijs L, Li Y, et al. Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population. Hypertension 2014; 64: 935-42.
34. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.
35. Franklin SS, O'Brien E, Staessen JA. Masked hypertension: understanding its complexity. Eur Heart J 2017; 38: 1112-8.
36. Verdecchia P, Reboldi GP, Angeli F, et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension 2005; 45: 203-8.
37. Briasoulis A, Androulakis E, Palla M, Papageorgiou N, Tousoulis D. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens 2016; 34: 593-9.
38. Stergiou GS, Asayama K, Thijs L, et al. Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome. Hypertension 2014; 63: 675-82.
39. Huang Y, Huang W, Mai W, et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens 2017; 35: 677-88.
40. Llisterri Caro JL, Rodriguez Roca GC, Alonso Moreno FJ, et al. Blood pressure control in hypertensive Spanish population attended in primary care setting: the PRESCAP 2010 study. Med Clin (Barc) 2012; 139: 653-61. (In Spanish.)